Riverpoint Wealth Management Holdings’s Alexion Pharmaceuticals ALXN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-1,109
Closed -$204K 83
2021
Q2
$204K Buy
+1,109
New +$190K 0.06% 82

Other funds holding ALXN

Riverpoint Wealth Management Holdings's ALXN Position: Q3 2021 in Review

Riverpoint Wealth Management Holdings sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,109 shares — an estimated $204K sold.

Riverpoint Wealth Management Holdings first reported a position in ALXN in Q2 2021 and held it in 1 quarter. The position peaked at $204K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Riverpoint Wealth Management Holdings reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Riverpoint Wealth Management Holdings sold 1,109 Alexion Pharmaceuticals shares in Q3 2021, an estimated $204K.
  • Riverpoint Wealth Management Holdings first reported a position in Alexion Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Riverpoint Wealth Management Holdings's Alexion Pharmaceuticals position peaked at $204K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Riverpoint Wealth Management Holdings's 13F filing for Q3 2021, filed 5 Nov 2021.